4 hours ago
At ATS 2026, pooled phase 3 data showed mepolizumab reduced COPD exacerbations and hospitalizations in patients with blood eosinophil counts starting at 150 cells/µL.
6 hours ago
Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the presentations that they’re looking forward to at ADA 2026.
8 hours ago
This interview at ATS 2026 highlights notable findings on the once-nightly oral pill, AD109, in obstructive sleep apnea (OSA).
9 hours ago
At ATS 2026, phase 3b ENCORE findings showed amikacin liposome inhalation suspension achieved high culture conversion rates in newly diagnosed MAC lung disease.
11 hours ago
Kyle Staller, MD, MPH, explains new real-world data showing 41% of IBS-C patients change treatments at least once, with each switch driving higher HCRU and provider portal burden.